加州大学圣迭戈分校研究人员发现，常用减肥药物Ozempic和Wegovy的活性成分司美鲁肽可能具有减缓生物衰老的作用[1]。这项随机对照试验首次在人类中提供了该药物可能影响衰老过程的证据，相关成果已发表在《自然通讯》期刊上[1]。
研究招募了108名患有HIV相关脂肪不均匀分布症的成人参与者，其中约半数接受周期性司美鲁肽注射，另一半接受安慰剂[1]。结果表明，司美鲁肽治疗组相比安慰剂组的生物衰老速度减慢了9%，这一测量基于DunedinPACE表观遗传时钟进行评估[1]。此外，另一项试验显示，42%的参与者生物衰老放缓，34%的参与者与全因死亡率相关的衰老出现放缓[1]。
研究团队负责人Michael Corley博士表示："我们不是说司美鲁肽逆转衰老或使人变年轻，我们看到的是它可能减缓与衰老相关的某些生物过程的信号"[1]。研究人员指出，这一发现的机制可能与药物减轻炎症和减少多余脂肪有关[1]，但他们强调需要进行更大规模的研究来确认这些初步发现[1]。
Researchers at the University of California, San Diego have found that semaglutide, the active ingredient in the weight-loss drugs Ozempic and Wegovy, may decelerate biological aging markers by reducing inflammation and decreasing excess fat.[1] A randomized controlled trial involving 108 adults with HIV-related lipodystrophy showed that participants receiving periodic semaglutide injections demonstrated a 9% slower rate of biological aging compared to those receiving placebo, as measured by the DunedinPACE epigenetic clock.[1] This marks the first time human evidence has suggested the medication may influence aging processes, with findings published in Nature Communications and npj Aging in 2026.[1]
However, researchers emphasized the scope of these findings.[1] "We are not saying semaglutide reverses aging or makes people younger; what we are seeing are signals that it may slow certain biological processes related to aging," Dr. Michael Corley stated.[1] A separate trial noted that 42% of participants showed slowed biological aging, while 34% demonstrated aging deceleration linked to all-cause mortality.[1] Despite these promising results, the research team indicated that larger-scale studies are necessary to confirm these observations and establish the drug's broader impact on aging processes.[1]